KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Leases (2016 - 2025)

Historic Capital Leases for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Q4 2025 value amounting to $720.0 million.

  • Regeneron Pharmaceuticals' Capital Leases changed 0.0% to $720.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $720.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $720.0 million for FY2025, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Capital Leases is $720.0 million, which was down 0.0% from $720.0 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Capital Leases high stood at $720.0 million for Q1 2022, and its period low was $720.0 million during Q1 2022.
  • Moreover, its 4-year median value for Capital Leases was $720.0 million (2022), whereas its average is $720.0 million.
  • The largest annual percentage gain for Regeneron Pharmaceuticals' Capital Leases in the last 5 years was 0.0% (2023), contrasted with its biggest fall of 0.0% (2023).
  • Quarter analysis of 4 years shows Regeneron Pharmaceuticals' Capital Leases stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
  • Its last three reported values are $720.0 million in Q4 2025, $720.0 million for Q3 2025, and $720.0 million during Q2 2025.